North America Head And Neck Cancer Therapeutics Market Size & Outlook
Related Markets
North America head and neck cancer therapeutics market highlights
- The North America head and neck cancer therapeutics market generated a revenue of USD 1,019.1 million in 2024.
- The market is expected to grow at a CAGR of 11.5% from 2025 to 2033.
- In terms of segment, immunotherapy was the largest revenue generating type in 2024.
- Immunotherapy is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2033.
North America data book summary
| Market revenue in 2024 | USD 1,019.1 million |
| Market revenue in 2033 | USD 2,695.5 million |
| Growth rate | 11.5% (CAGR from 2025 to 2033) |
| Largest segment | Immunotherapy |
| Fastest growing segment | Immunotherapy |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
| Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
Other key industry trends
- In terms of revenue, North America region accounted for 44.8% of the global head and neck cancer therapeutics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,143.3 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Head And Neck Cancer Therapeutics Market Scope
Head And Neck Cancer Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Clinigen Group | View profile | 1001-5000 | Burton-on-trent, St. Helens, United Kingdom, Europe | http://clinigengroup.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
North America head and neck cancer therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 67.06% in 2024. Horizon Databook has segmented the North America head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2021 to 2033.
North America dominated the global head and neck cancer therapeutics market in 2022. The rising prevalence of head & neck cancer and the highly advanced healthcare infrastructure are key factors influencing the regional market growth.
For instance, according to the American Society of Clinical Oncology (ASCO), in the U.S., about 66,920 new head and neck cancer cases were estimated to be diagnosed in 2023. Similarly, in Canada, according to the Canadian Cancer Society in 2023, about 7,900 new head and neck cancer cases were estimated to be diagnosed in 2023.
The rise in approvals for cancer therapeutics, specifically for head and neck cancer, is anticipated to fuel the market in the near future. For instance, in March 2023, Incyte received the U.S. FDA approval for its Incyte PD-1 inhibitor for treating metastatic Merkel Cell Carcinoma (MCC).
Reasons to subscribe to North America head and neck cancer therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America head and neck cancer therapeutics market databook
-
Our clientele includes a mix of head and neck cancer therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America head and neck cancer therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into North America head and neck cancer therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
North America head and neck cancer therapeutics market size, by country, 2021-2033 (US$M)
North America Head And Neck Cancer Therapeutics Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
